



The Nifty previous session ended 1.02% up at 17805.25. It opened on a bullish note and continued rising relentlessly towards finishing off the day above 17730. Ending near day's high suggesting it may challenge 17830 in next few sessions. Higher resistance is placed around 17930. Immediate trading range likely to be 17640-17930.

On the Nifty hourly chart, ending above the critical MA band for the second consecutive session is a positive development, which is likely to act as the immediate support. Intraday range likely to be 17640-17930.

Nifty patterns on multiple periods suggest; ending the session above 17730 itself suggesting continuation of current pullback. Bullish momentum likely to sustain as long as it trades above 17500 levels.

Nifty Crucial Supports & Resistances-

Supports- 17640, 17500 Resistances- 17830, 17930

Open Positional Calls-

- T+5 Positional Sell-
|Futures Segment| SAIL Fut @ 111-112,
TGT- 102, Closing SL- closing above 117
- T+14 INST POSITIONAL SELL
|Futures Segment| UPL Jan Fut @ 770-
775, TGT- 705, SL- closing above 810
- T+10 INST POSITIONAL BUY
|Cash Segment| IPCA LAB @ 2160-2150,
TGT- 2270, SL- closing below 2090
- T+2 Positional Sell-
|Futures Segment| COAL IND Fut @ 154-
155, TGT- 149, SL- closing above 158
- T+2 BUY
|Cash Segment| HCL TECH @ 1335-1330,
TGT- 1360, SL- closing below 1315
- BTST
|Cash Segment| MC DOWELL @ 912-
910, TGT- 930, SL- closing below 900

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks advanced for the third consecutive session, aided by banking, power and energy stocks.

Nifty index ended 1.02% higher at 17,805. The broader markets represented by the NIFTY 500 Index ended 0.75% higher, ending at 15,319. Among the sectorial indices NIFTY Energy was the top gainer, gaining by 2.28%, followed by NIFTY PSE was gaining by 1.63%. NIFTY Pharma was the top loser losing by 0.82%.

NTPC was the top gainer, gaining by 5.48%, followed by ONGC and Power Grid gained by 3.32% & 2.73% respectively. Tata Motors was the top loser, losing by 1.61%, followed by Coal India and Sun Pharma which fell by 1.48% & 1.33% respectively.

The Advance : Decline ratio stood at 1118:1015

Market Turnover (In Crore) 04-01-2022

Name	Last	Previous
NSE Cash	55309.95	47115.27
NSE F&O	7041073.06	5410151.04
BSE Cash	5,196.40	4,739.27
BSE F&O	*NA	77.34

FII Derivatives Flow (In Crore) 03-01-2022*

Instrument	Purchase	Sale	Net
Index Future	4433.54	3771.56	661.98
Index Option	411869.96	413056.28	1186.32
Stock Future	10323.16	10669.55	346.39
Stock Option	9391.39	9181.29	210.1

Institutional Flow (In Crore) 04-01-2022

Institution	Purchase	Sale	Net
FII	5834.72	4560.86	1273.86
DII	5250.38	4717.41	532.97

*Data not updated till 7PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
NTPC	5.48	7.09	33986738	13211130
ONGC	3.32	5.95	16351836	7405114
Power Grid	2.73	2.43	11088068	20646400
SBI	2.70	4.84	23296671	14519810
Titan	2.34	8.54	1037293	1187252

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Shree Cement	1.08	0.89	26215	23873
Tata Con Products	1.22	1.64	2352482	1125021
Sun Pharmaceutical	1.33	2.77	3027262	5295953
Coal India	1.48	2.79	13744440	13742660
Tata Motors	1.61	1.96	24100985	18667730

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59855.93	672.71	1.14	3.38	3.74	0.94	24.24
Nifty	17805.25	179.55	1.02	3.32	3.54	0.64	25.98
BSE M Cap	25257.28	12.46	0.05	2.45	0.30	1.35	37.11
BSE S Cap	29925.67	117.72	0.39	3.47	5.29	4.28	61.67
Nifty MC 100	30870.35	82.35	0.27	2.58	1.91	0.02	44.33
BSE Auto	25225.53	52.13	0.21	3.24	3.37	5.57	18.40
BSE Capgoods	29366.44	244.13	0.84	2.74	6.52	11.72	52.74
BSE FMCG	13911.50	101.67	0.74	2.03	1.32	6.59	8.77
BSE Metal	19544.57	109.34	0.56	1.46	3.30	6.24	59.85
BSE Oil&Gas	17914.27	205.49	1.16	1.82	0.78	2.77	24.26
BSE Healthcare	25958.53	193.01	0.74	2.10	3.21	2.59	17.71
BSE Power	3582.16	78.79	2.25	1.82	1.27	9.33	71.29
BSE Realty	3861.50	22.68	0.58	0.72	0.25	6.52	54.04
BSE ConsDur	45508.17	330.03	0.73	4.06	5.60	9.26	49.92
BSE Bank	41982.20	543.43	1.31	4.88	1.92	2.13	17.45
BSE IT	38376.32	181.21	0.47	2.32	9.49	11.12	52.69

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.63	0.00	0.00	9.95	21.22	10.08	78.27
UK	1.04	0.07	7.11	12.43	39.22	2.87	501.16
Brazil	4.59	0.07	1.44	0.18	0.93	6.16	42.45
Japan	0.09	0.02	23.94	39.68	66.04	62.96	319.05
Australia	1.75	0.08	4.61	10.78	8.51	17.25	71.78
India	6.52	0.06	0.87	0.74	2.31	4.31	11.88
Switzerland	0.10	0.00	2.02	44.81	64.31	40.59	82.47
Germany	0.14	0.02	18.64	40.68	63.92	34.58	76.82

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.56	0.30	0.40	0.13	1.16	0.33	2.06
USD Index	96.25	0.03	0.03	0.04	0.13	2.63	7.09
YUAN	6.37	0.02	0.27	0.08	0.04	1.12	1.38
GBP	1.35	0.00	0.11	0.45	1.74	0.85	0.56
EUR	1.13	0.00	0.04	0.16	0.06	2.83	7.81
YEN	115.94	0.62	0.53	0.97	2.12	4.32	11.05

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2217.00	2.00	0.09	6.81	19.88	53.00	62.30
Baltic Dirty	786.00	2.00	0.25	0.25	6.65	24.76	68.67
SG Dubai HY	6.00	0.11	1.80	7.55	4.91	129.89	450.46

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	36585.06	246.76	0.68	0.78	5.80	7.59	21.05
Nasdaq	15832.80	187.83	1.20	0.24	4.95	11.06	24.68
S&P 500	4796.56	30.38	0.64	0.11	5.69	11.54	29.61
FTSE100	7477.90	93.57	1.27	1.42	5.00	6.42	15.75
CAC40	7304.92	88.97	1.23	1.74	7.99	12.79	30.73
DAX	16119.29	101.55	0.63	1.81	6.28	7.22	17.45
Mexico IPC	52941.01	331.42	0.62	0.60	4.63	4.09	18.43
Brazil Bovespa	103921.6	900.80	0.86	0.92	1.09	5.86	12.56
Russian RTS	1631.73	10.04	0.62	1.86	2.13	8.57	14.59
Japan Nikkei	29301.79	510.08	1.77	1.80	5.32	0.51	6.77
Hang Seng	23289.84	15.09	0.06	0.04	2.01	3.11	15.23
Taiwan Index	18526.35	255.84	1.40	2.65	4.69	12.91	24.32
Shanghai Comp	3632.33	7.45	0.20	0.45	0.69	1.80	4.59
KOSPI	2989.24	0.47	0.02	0.34	0.70	0.99	1.52
Malaysia KLCI	1541.90	7.15	0.46	0.13	2.67	1.28	3.79
Jakarta Comp	6695.38	30.07	0.45	1.82	2.40	5.56	9.67
Philippine SE	7041.27	81.36	1.14	1.96	0.20	1.15	2.17
Thai Exch	1670.28	12.66	0.76	2.02	6.48	4.02	15.24

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	76.65	0.54	0.71	0.84	15.64	1.29	60.90
BRENT Crude	79.56	0.54	0.68	1.08	14.40	0.72	59.29
Natural Gas	3.83	0.02	0.42	1.39	5.94	34.94	27.83

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1805.36	4.00	0.22	0.04	1.24	2.03	7.07
Silver(\$/Ounce)	22.83	0.06	0.28	0.80	1.38	0.68	16.16
Aluminium	2806.00	22.25	0.79	0.19	6.50	1.28	42.18
Copper	9740.63	16.63	0.17	1.05	2.37	8.90	25.70
Zinc	3590.00	10.00	0.28	0.52	9.16	20.64	31.53
Lead	2337.75	11.00	0.47	0.04	0.84	10.27	18.32

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	225.10	1.80	0.81	0.22	7.50	10.75	67.42
Cotton	114.46	1.23	1.09	4.01	9.85	11.57	51.14
Sugar	18.78	0.04	0.21	0.95	0.16	4.62	29.43
Wheat	759.75	1.75	0.23	3.03	5.47	1.11	17.84
Soybean	1367.50	12.00	0.89	0.04	7.57	8.94	24.69

iD Fresh raises Rs 507 Cr, Helion exits with 10x returns

Billionaire Azium Premji-backed ready-to-cook product company iD Fresh Food on Tuesday announced it has closed Rs 507 crore series-D round of funding. Private equity firm NewQuest Capital Partners led the round along with the existing investor. Early investor Helion Ventures exited with a 10x return. The strategic fund raise is aimed at further strengthening iD's market leadership in the fresh foods business, fostering product innovation, building capacities and expanding its presence across key markets in India, the UAE, and the US. As part of its global expansion plans, the company plans to extend its presence to Singapore, Malaysia and other markets in the near future.

L&T Construction bags significant order from DMRC

L&T on its construction business has bagged a significant order from Delhi Metro Rail Corporation Ltd for the design and construction of the underground metro project Phase-1 of Patna Mass Rapid Transit System. The order has been awarded to heavy civil infrastructure business of L&T Construction. Larsen and Toubro (L&T) classifies a contract worth Rs 1,000-2,500 crore as a significant order. The project is being funded by Patna Metro Rail Corporation (PMRC) and, upon completion, will be operated by PMRC. The project alignment passes through the heart of Patna city and is scheduled to be completed within 42 months.

YES Bank net advances up by 4% to Rs 1,76,422 crore by December-end

YES Bank's net advances grew by nearly 4 per cent to Rs 1,76,422 crore on a provisional basis as of December 31, 2021, the bank said on Tuesday. Net advances amounted to Rs 1,69,721 crore as of December 31, 2020. According to the provisional data released by the bank, the gross retail disbursements during the December quarter was Rs 9,233 crore, up from Rs 7,470 crore in year ago quarter. The deposits rose by 26 per cent year-on-year to Rs 1,84,289 crore at end of December 2021, as against Rs 146,233 crore. Bank's credit to deposit ratio was 95.7 per cent at December 31, 2021 as compared with 116.1 per cent from the same period a year ago.

Bank of Maharashtra's gross advances rise to Rs 1.29 lakh crore at end of December 2021

Bank of Maharashtra has registered over 23 per cent growth in gross advances to Rs 1,29,052 crore at the end of December 2021. The bank's gross advances stood at Rs 1,04,904 crore at the end of December 31, 2020. According to a regulatory filing, deposits grew by 15.21 per cent to Rs 1,86,614 crore in the period under review as against Rs 1,61,971 crore in the year-ago period. The bank's total business was up by 18.28 per cent to Rs 3,15,666 crore from Rs 2,66,875 crore. The CASA (Current Account Savings Account) ratio was at 55.05 per cent at the end of December 2021. Gross investments were up by 12 per cent to Rs 72,328 crore at the end of December 2021 from Rs 64,638 crore in the year-ago period.

Dr Reddy's launches molnupiravir at Rs 35 per pill, matching Mankind's price

Dr. Reddy's on Tuesday said it will launch its COVID-19 antiviral molnupiravir capsules under its brand name Molflu across India at matching the price of Mankind Pharma. Dr. Reddy's Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 days costing Rs. 1,400 making it among the most affordable treatment options available to patients. Mankind Pharma's Molulife (brand name) is also expected to cost Rs 1,400, RC Juneja, chairman of Mankind Pharma.

Amp Energy commissions 30 MW solar project for Bosch

Amp Energy India on Tuesday said it has commissioned a 30 MW solar power project for Bosch Ltd. The solar project capacity would be provided from Amp Energy India's open access facility in Raichur district of Karnataka. This is Amp's third open access project in Karnataka. Bosch and Amp Energy have signed a power purchase agreement for procurement of solar power for 25 years. The solar open access facility commissioned this month will generate about 43 million units of green energy per year for Bosch and will meet about 40 per cent of their energy consumption. This project will provide solar power to energize Bosch's plants/facilities in and around Bengaluru and by switching to solar power, Bosch will also help mitigate about 31,000 tonne of CO2 per annum.

L&T Construction bags significant order from DMRC

L&T on Tuesday said its construction business has bagged a significant order from Delhi Metro Rail Corporation Ltd for the design and construction of the underground metro project Phase-1 of Patna Mass Rapid Transit System. The order has been awarded to heavy civil infrastructure business of L&T Construction. Larsen and Toubro (L&T) classifies a contract worth Rs 1,000-2,500 crore as a significant order. The project is being funded by Patna Metro Rail Corporation (PMRC) and, upon completion, will be operated by PMRC. The project alignment passes through the heart of Patna city and is scheduled to be completed within 42 months.

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market Doxycycline Hyclate delayed-release tablets, used to treat drug resistant bacterial infections, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxycycline Hyclate delayed-release tablets. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Doryx Tablets, 75 mg, 100 mg, 150 mg, and 200 mg, of Mayne Pharma International Pty Ltd (Mayne). Doxycycline Hyclate delayed-release tablets are indicated to reduce the development of drug resistant bacteria. According to IQVIA data, Doxycycline Hyclate delayed-release tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg have an estimated market size of USD 10 million for twelve months ending September 2021.

Sterlite Power commissions Khargone transmission project worth Rs 1,662 crore in MP

Sterlite Power on Tuesday announced successful commissioning of Khargone transmission project worth Rs 1,662 crore in Madhya Pradesh. The project will evacuate 1,320 MW of power generated by the Khargone Power Plant to 765 kV Khandwa substation to further distribute it downstream across Madhya Pradesh, Maharashtra, Chhattisgarh, Gujarat, Goa, Daman & Diu, and Dadra & Nagar Haveli. With the completion of the 765 kV D/C Khandwa - Dhule transmission line, all the elements in the project are complete and charged. In April 2020, the company had already commissioned 5 out of 6 elements in the project which includes, 765kV substation at Khandwa, 400kV D/C Khandwa-Khargone transmission line, 765kV DC Khandwa-Indore transmission line, 400kV LILO and Dhule bay extension. The company had won KTL through tariff-based competitive bidding (TBCB).

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Johnson Pharmacare Ltd	10 for 1 stock split effective 05-01-2022

Domestic Events

- India Markit Composite and Services PMI for December 2021.

Global Events

- China Consumer Confidence for December 2021.
- Japan Consumer Confidence for December 2021.
- Euro Area Markit Composite and Services PMI for December 2021.
- The U.S. MBA Mortgage Applications for December 31, 2021.
- The U.S. ADP Employment Change for December 2021.
- The U.S. Markit Composite and Services PMI for December 2021.
- The U.S. FOMC Minutes.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey and Deepankar Saha Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
